PUBLISHER: DelveInsight | PRODUCT CODE: 1226632
PUBLISHER: DelveInsight | PRODUCT CODE: 1226632
"MM-120 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MM-120 for Generalized Anxiety Disorder (GAD) in the seven major markets. A detailed picture of the MM-120 for Generalized Anxiety Disorder in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the MM-120 for Generalized Anxiety Disorder. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MM-120 market forecast, analysis for Generalized Anxiety Disorder in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Generalized Anxiety Disorder.
MM-120 is MindMed's proprietary drug candidate, which is a pharmacologically optimized form of lysergic acid diethylamide (LSD; it has been investigated for its applications in the treatment of anxiety associated with terminal cancer, alcoholism, opioid use disorder, and depression, among other conditions). The drug is a psychedelic drug which is being developed for GAD and other brain-based disorders and can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages, MM-120 manifests primarily in visual as well as auditory hallucinations.
In August 2022, the company initiated patient dosing in the Phase IIb dose-optimization study of MM-120 for the treatment of GAD. Patient enrollment is currently ongoing, and topline results are expected in late 2023.
The Company continues to prioritize and focus its current development efforts and resources on MM-120 in psychiatric indications. MindMed currently owns and retains all clinical data and manufacturing rights for MM-120 and is aggressively protecting and expanding its intellectual property portfolio.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
MM-120 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of MM-120 in Generalized Anxiety Disorder in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data of MM-120.
The report provides the clinical trials information of MM-120 in Generalized Anxiety Disorder covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions